AbbVie and Genentech Join White House Discounted Drug Site Monday

AbbVie's blockbuster Humira and Genentech's flu treatment Xofluza went live on TrumpRx Monday, making the two pharmaceutical giants the 10th and 11th companies to list drugs on the White House's direct-to-consumer discount platform. The additions expand a program that launched in February with 43 medications, bringing more high-cost specialty drugs within reach of a specific, narrow slice of American patients.

AbbVie, which struck a deal with the Trump administration in January, will sell Humira, used to treat rheumatoid arthritis, Crohn's disease, and ulcerative colitis, at an 86% discount. Prices for the Humira Pen, also known by its generic name adalimumab, can exceed $6,900 for uninsured individuals. At the 86% discount rate, that puts a monthly supply closer to $966. AbbVie's other drugs offered through the platform include the glaucoma treatments Alphagan and Combigan and the thyroid medication Synthroid.

Genentech, a unit of Roche, signed its agreement in December alongside eight other major drugmakers, and its flu treatment Xofluza will be available for $50, representing a 70% reduction from list price.

The discounts are real, but the eligibility wall is equally significant. The prescription prices on TrumpRx are only available to patients who are uninsured, or whose insurance doesn't cover a given medication, and who must pay the full list price out of pocket. Those with insurance coverage generally pay lower prices already. That effectively excludes most commercially insured Americans, and it leaves Medicare and Medicaid enrollees largely untouched for now. A White House official said the administration is working to codify the discount deals through the "Great Healthcare Plan" to eventually allow people on government insurance to use copays for TrumpRx drugs, though no timeline for that change has been announced.

The incentives driving AbbVie and Genentech to the table go beyond altruism. Companies aligning with the Most Favored Nation pricing strategy receive a three-year tariff suspension. AbbVie also pledged $100 billion in U.S.-based research, development, and capital investments, including manufacturing projects, over the next decade as part of its January agreement, giving the deal the character of a broad political compact as much as a pricing reform. Critics have noted that the arrangement leaves rebate negotiations between drugmakers and pharmacy benefit managers intact for insured patients, meaning the structural forces that drive up list prices remain largely undisturbed.

TrumpRx does not sell medications directly. Instead, it provides coupons that can be redeemed at pharmacies or through manufacturer direct-to-consumer sites, and specific medications carry unique qualifications users must meet to obtain a coupon. Analysts have also flagged that roughly half the drugs listed on TrumpRx are available as generics at prices well below the discounted brand-name rates, limiting the program's practical reach even among uninsured shoppers.

The White House has signaled that more companies and more drugs are coming, with roughly 16 Most Favored Nation deals now signed. Whether the expanding roster of participating drugmakers translates into broad relief for the patients with the highest drug bills, particularly Medicare enrollees with complex chronic conditions, will depend on whether the administration follows through on extending eligibility well beyond those already paying cash.